Page 47 - CIBER-BBN2016-ENG

Most relevant scientific articles
• Pinto-Fraga J., López-Miguel A., González-García M.J., Fernández I., López-De-La-Rosa A., Enríquez- de-Salamanca A. et al. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial. Ophthalmology. 2016;123(1):141-153.
• Cocho L., Fernández I., Calonge M., Martínez V., González-García M.J., Caballero D. et al. Biomarkers in ocular chronic graft versus host disease: Tear cytokine- and chemokine-based predictive model. Investigative Ophthalmology and Visual Science. 2016;57(2):746-758.
• Sobas E.M., Reinoso R., Cuadrado-Asensio R., Fernández I., Maldonado M.J., Pastor J.C. Reliability of potential pain biomarkers in the saliva of healthy subjects: Inter-individual differences and intersession variability. PLoS ONE. 2016;11(12).
• López-Paniagua M., Nieto-Miguel T., de la Mata A., Galindo S., Herreras J.M., Corrales R.M. et al. Successful Consecutive Expansion of Limbal Explants Using a Biosafe Culture Medium under Feeder Layer-Free Conditions. Current Eye Research. 2016;:1-11.
• López-Paniagua M., Nieto-Miguel T., de la Mata A., Dziasko M., Galindo S., Rey E. et al. Comparison of functional limbal epithelial stem cell isolation methods. Experimental Eye Research. 2016;146:83-94.
Highlights
IOBA-UVa group is working in TWO intramural projects:
• BioScaff-EYE: “Bio-engineered Stem Cell Niches in Ocular Surface Reconstruction for Corneal
Blindness”, coordinated by IOBA-UVa was transferred to Ferrer (Ferrer International SA) in 2014. Originally three groups are working: IOBA-UVa-Valladolid, clinical-basic research group (PI: M. Calonge, IBEC-Barcelona (PI: E. Engel), and NanoBioCel-Vitoria (PI: JL. Pedraz), both basic research groups, along with the research department of Ferrer Advanced Biotherapeutics. During 2016, a European patent application was filed claiming the polymeric membranes and their potential application in the field
of ocular surface stem cell deficiency and its repair. Additionally, the necessary industrial escalation was accomplished by IBEC and FAB, transferring the procedures to a GMP-operating company, where they are optimizing the production along with IOBA-UVa input, meaning lots of in-vitro and in-vivo experimental procedures back and forth. The cellular component has also started its GMP-producing phase in a company specialized in this kind of development.
• EYEPOC-II: “Point Of Care Biosensor Devices To Detect Biomarkers As Evaluation End-Points For Therapeutic Clinical Trials In Ocular Surface Inflammation”, granted in 2014, renewed in 2016. It is coordinated by IOBA-UVa, the clinical-basic research group (PI: A. Enríquez-de-Salamanca), NB4D-CISC (PI: R. Galve), CIN2-CISC (PI: L. Lechuga) and GQNA-CISC (PI: R. Eritja). During 2016 we worked on WP1, Analysis of microRNAs expression in Dry Eye Disease (DED) patients’ conjunctival epithelial cells and/ or tears. Patients and controls were recruited and clinically under controlled environmental conditions (constant temperature (22oC) and relative humidity (40%), in our environmental chamber, IOBA- CERLab). (tasks 1.1-1.2). Samples (tears and conjunctival impression cytologies (CIC)) were collected
for microRNA evaluation (task 1.3). Task 1.4 (Micro RNA analysis) was initiated, including CIC miRNA isolation/quantification. Our previous results in pooled samples showed encouraging alterations in the levels of some molecules. We are already collecting samples in patients and healthy subjects to evaluate the levels of 84 inflammation-related microRNAs by RT-PCR in individual samples.
BBN
Research Groups 47